Health Canada approves Chiesi’s MYALEPTA for lipodystrophy
06 Feb 2024
Drug ApprovalAcquisition
Preview
Source: Pharmaceutical Technology
The safety and efficacy of the asset in treating metabolic disorders linked to lipodystrophy syndromes were evaluated in an open-label, single-arm study. Credit: MikeSaran / shutterstock.com.
Health Canada has approved Chiesi Group unit Chiesi Global Rare Diseases’ MYALEPTA (metreleptin for injection) to treat individuals with lipodystrophy, an ultra-rare condition.
MYALEPTA is a replacement therapy adjunct to diet to address complications of leptin deficiency in patients with congenital or acquired forms of the disease.
MYALEPTA can be used in adults and children aged two and above with confirmed congenital generalised lipodystrophy (Berardinelli-Seip syndrome) or acquired generalised lipodystrophy (Lawrence syndrome).
It is also approved for patients aged 12 years and above with familial partial lipodystrophy (PL) or acquired PL (Barraquer-Simons syndrome). The treatment is intended for patients with metabolic disease who have not achieved adequate metabolic control with conventional treatments.
MYALEPTA is originally developed by Amryt Pharma. Chiesi Group gained access to MYALEPTA through the acquisition of Amryt in April 2023.
See Also:UK MHRA approves GSK’s momelotinib for myelofibrosis anaemia
Preview
Source: Pharmaceutical Technology
Germany’s Ministry of Health refutes accusations of worsening market conditions
Preview
Source: Pharmaceutical Technology
The safety and efficacy of the asset in treating metabolic disorders linked to lipodystrophy syndromes were evaluated in a long-term, open-label, single-arm study.
The research was conducted under the supervision of the US National Institutes of Health.
Weight decrease, hypoglycaemia and fatigue were the most commonly observed adverse drug reactions linked to the treatment.
Chiesi Group Global Rare Diseases head Giacomo Chiesi stated: “We are very proud of the partnership that we have developed with Medison and applaud the team for their efforts to bring this innovative and important treatment to patients in Canada.
“At the Chiesi Group, we are committed to creating a difference in the lives of patients with rare diseases and in collaboration with the Medison team, we have been able to achieve this for those living with lipodystrophy.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.